Hypothetically zinc level reflects the continuum from “low-risk” steroid-positive (luminal) breast cancers (with options for antitumor treatment via the respective target-receptor) via “intermediate-risk” Her2-positive breast cancers (with options for Her2-targeted therapy) to finally autonomous TNBC without any targets for cancer regulation. The gene discussed is ERBB2; the disease is breast cancer.